Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuebijing is a traditional Chinese medicine (TCM) injection developed by Tianjin Chase Sun Pharmaceutical for the treatment of sepsis, systemic inflammatory response syndrome (SIRS), and multiple organ dysfunction syndrome (MODS). It is a complex botanical extract derived from five medicinal herbs: *Carthamus tinctorius* (safflower), *Paeonia lactiflora* (red peony root), *Ligusticum chuanxiong* (chuanxiong), *Salvia miltiorrhiza* (danshen), and *Angelica sinensis* (dang-gui). The drug functions by inhibiting the cytokine storm associated with severe infection, specifically targeting pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, and HMGB1. Additionally, it helps regulate the coagulation system and improves microcirculation. Xuebijing is widely used in intensive care units in China and gained international attention for its inclusion in the national clinical guidelines for the treatment of COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xuebijing.